[{"orgOrder":0,"company":"Lotus Pharmaceutical Industries","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Lotus Pharmaceutical Industries","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical Industries","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Lotus Pharmaceutical Industries","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lotus Pharmaceutical Industries","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.34999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Lotus Pharmaceutical Industries","sponsor":"Teva Pharma (Thailand)","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"THAILAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical Industries \/ Lotus Pharmaceutical Industries"}]

Find Clinical Drug Pipeline Developments & Deals by Lotus Pharmaceutical Industries

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including NATEAR (hydroxypropyl methylcellulose) used as artificial tears to prevent conjunctival and corneal damage.

                          Product Name : Natear

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 06, 2024

                          Lead Product(s) : Hydroxypropyl Methyl Cellulose

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Recipient : Teva Pharma (Thailand)

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The partnership aims to distribute and commercialize Vazkepa (icosapent ethyl), approved and commercialized in a number of global markets, including the U.S. and European markets, across 10 countries, including nine in Southeast Asia and South Korea.

                          Product Name : Vazkepa

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 31, 2023

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Amarin

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The collaboration aims to develop and commercialize NRX-101, an fixed dose oral combination of D-cycloserine and lurasidone for treatment-resistant suicidal bipolar depression (S-TRBD). It is one of the first oral antidepressants targeting the NMDA recep...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $10.0 million

                          July 06, 2023

                          Lead Product(s) : Cycloserine,Lurasidone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : NRx Pharmaceuticals

                          Deal Size : $345.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Cialis® (tadalafil), is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, and Cialis® is positioned as the top 2 brand product for erectile dysfunction treatment with high brand loyalty.

                          Product Name : Cialis

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 22, 2022

                          Lead Product(s) : Tadalafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Recipient : Eli Lilly

                          Deal Size : $57.5 million

                          Deal Type : Acquisition

                          blank